Meeting News Coverage

First-line everolimus plus exemestane prolonged PFS in advanced breast cancer

September 18, 2013
The addition of the mTOR inhibitor everolimus to first-line exemestane therapy extended PFS compared with exemestane alone in patients with hormone…
Meeting News Coverage

Genetic variations influence everolimus benefit in advanced breast cancer

September 16, 2013
Women with hormone receptor-positive, HER-2–negative advanced breast cancer who had minimal genetic variations in PI3K, FGFR or CCND1
Meeting News Coverage

Survival after CNS metastases varied by breast cancer subtype

September 11, 2013
Survival among patients with central nervous system metastases who underwent cranial radiation varied considerably based on breast cancer subtype…
Meeting News Coverage

Expanded access study confirms Kadcyla safe, active in pretreated HER-2–positive breast cancer

September 9, 2013
Ado-trastuzumab emtansine appeared safe and effective in previously treated patients with HER-2–positive locally advanced or metastatic breast…
Meeting News Coverage

Age alone predicted survival in patients with brain metastasis

September 6, 2013
Age at diagnosis was associated with shorter survival in patients with brain metastasis from breast cancer who underwent craniotomy and resection…
Meeting News CoveragePerspective

90% of women miscalculated their risk for breast cancer

September 5, 2013
More than 90% of women inaccurately perceived their breast cancer risk, according to results of a large-scale, multicenter survey presented at the…
Meeting News CoveragePerspective

Radiation therapy for DCIS did not increase risk for cardiovascular disease

September 4, 2013
Women who underwent radiation therapy for ductal carcinoma in situ of the breast demonstrated no additional risk for cardiovascular disease…